Kiralis Technologies

Enantiomer Separation

Health Tech & Life Sciences
Non Active, Mar 2022 ceased to operate
Seed , Israel Founded 2018
Last updated 2026-06-18
Total raised
$3.0M
Last: 2018-09
Stage
Seed
Founded
2018
Headcount
3
HQ
, Israel
Sector
Health Tech & Life Sciences

About

Kiralis Technologies is developing a commercial-level application for separating chiral molecules with only minor modifications for each class of racemic solution in order to achieve a high-purity repeatable product. The technology targets racemic solutions that are not separated in the pharmaceutical, pesticide, herbicide, flavor, or fragrance markets. This process was enabled by the discovery of chiral-induced spin selectivity by Professor Naaman from the Weizmann Institute and Professor Paltiel from the Hebrew University, who discovered a phenomenon they defined as chiral-induced spin selectivity (CISS). In a May 2018 article in Science, they demonstrated how the CISS effect could be exploited to separate enantiomers in a racemic mixture through the application of a magnetic field.

Funding history · 1 round · $3.0M total

2018-09

Q&A

What is the primary focus of Kiralis Technologies?
Kiralis Technologies is developing a commercial-level application for separating chiral molecules with minor modifications for each class of racemic solution to achieve a high-purity repeatable product.
When was Kiralis Technologies founded?
Kiralis Technologies was founded in September 2018.
What is the current operational status of Kiralis Technologies?
Kiralis Technologies is currently inactive, having ceased operations in March 2022.
Which sector does Kiralis Technologies primarily operate in?
Kiralis Technologies primarily operates in the Health Tech & Life Sciences sector, specifically focusing on Pharma & Medical Biotechnology and Drugs Discovery & Development.
How many employees does Kiralis Technologies have?
Kiralis Technologies has 1-10 employees.
What is the total amount of funding raised by Kiralis Technologies?
Kiralis Technologies has raised a total of $3,000,000.
Which investor participated in Kiralis Technologies' funding round?
Grove Ventures participated in Kiralis Technologies' funding round in September 2018.
Who is a co-founder and CTO of Kiralis Technologies?
Eyal Capua is a Co-founder and CTO of Kiralis Technologies.

Team · 1

Eyal Capua
Founder · Co-founder & CTO

Sectors & technology

Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsMolecules
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticalsIndustrial ManufacturingAgriculture & FoodProcessed Foods
Business model
B2B

Highlights

1 PatentsVerified

Tags

healthcare-providersbiotechnologypharmaceuticalsagtechchemicalsagriculture
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)